CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.5. ANALYST TOOLS AND MODELS
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry
3.4. MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY MARKET, 2015
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY
4.1. OVERVIEW
4.1.1. Market Size and Forecast
4.2. MONOCLONAL ANTIBODIES
4.2.1. Key Market Trends
4.2.2. Key Growth Factors and Opportunities
4.2.3. Market Size and Forecast
4.4. CYTOKINES & IMMUNOMODULATORS
4.4.1. Key Market Trends
4.4.2. Key Growth Factors And Opportunities
4.4.3. Market Size And Forecast
4.5. OTHER TECHNOLOGY
4.5.1. Key Market Trends
4.5.2. Key Growth Factors And Opportunities
4.5.3. Market Size And Forecast
CHAPTER 5 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. LUNG CANCER
5.2.1. Market size and forecast
5.3. BREAST CANCER
5.3.1. Market size and forecast
5.4. COLORECTAL CANCER
5.4.1. Market size and forecast
5.5. MELANOMA
5.5.1. Market size and forecast
5.6. PROSTATE CANCER
5.6.1. Market size and forecast
5.7. HEAD & NECK CANCER
5.7.1. Market size and forecast
5.8. OTHER CANCER
5.8.1. Market size and forecast
CHAPTER 6 CANCER IMMUNOTHERAPY MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITAL
6.2.1. Market size and forecast
6.3. CANCER RESEARCH CENTERS
6.3.1. Market size and forecast
6.4. CLINICS
6.4.1. Market size and forecast
CHAPTER 7 MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities.
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. AMGEN INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. ADVAXIS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. MERCK & CO., INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. ELI LILLY AND COMPANY
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. BRISTOL-MYERS SQUIBB COMPANY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. PFIZER INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NOVARTIS AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. BAYER AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. IMMUNOMEDICS INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. ASTRAZENECA PLC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments